Carol Stuckley
Direktor/Vorstandsmitglied bei CENTESSA PHARMACEUTICALS PLC
Vermögen: - $ am 30.04.2024
Profil
Carol Stuckley currently works at Transgene SA, as Independent Director from 2023 and Centessa Pharmaceuticals Plc, as Independent Non-Executive Director from 2021.
Ms. Stuckley also formerly worked at Ipsen SA, as Independent Director from 2017 to 2021, Epizyme, Inc., as Independent Director from 2021 to 2022, Financial Executives International of Fort Worth Chapter, as President & Director, Pfizer Inc., as Vice President-Finance & Assistant Treasurer, Galderma Laboratories LP, as Chief Financial Officer & Senior VP-Finance from 2010 to 2013, and Healthcare Payment Specialists LLC, as Chief Financial Officer & Senior Vice President from 2015 to 2019.
Ms. Stuckley received her undergraduate degree in 1977 from the University of Delaware and graduate degree in 1980 and Masters Business Admin degree in 1979 from Fox School of Business.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
19.03.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Carol Stuckley
Unternehmen | Position | Beginn |
---|---|---|
CENTESSA PHARMACEUTICALS PLC | Direktor/Vorstandsmitglied | 17.05.2021 |
TRANSGENE | Direktor/Vorstandsmitglied | 05.05.2023 |
Ehemalige bekannte Positionen von Carol Stuckley
Unternehmen | Position | Ende |
---|---|---|
EPIZYME, INC. | Direktor/Vorstandsmitglied | 12.08.2022 |
IPSEN | Direktor/Vorstandsmitglied | 01.08.2021 |
Healthcare Payment Specialists LLC
Healthcare Payment Specialists LLC Miscellaneous Commercial ServicesCommercial Services Healthcare Payment Specialists LLC provides payment and reimbursement solutions. The firm’s solutions include Stingary SAAS, Medicare bad debt, Medicare disproportionate share, Shadow billing compliance, Transfer DRG, Volume decrease adjustment and Complex drug review. It also offers consulting services. The company was founded in 2002 by Peter Jarvis and is headquartered in Fort Worth, TX. | Finanzdirektor/CFO | 01.07.2019 |
Galderma Laboratories LP
Galderma Laboratories LP Pharmaceuticals: MajorHealth Technology Galderma Laboratories LP develops and markets dermatology and prescription products. It also offers treatments for skin conditions such as acne, rosacea, atopic dermatitis, soriasis, melasma and sunspots. Galderma Laboratories was founded in 1961 and is headquartered in Fort Worth, TX. | Finanzdirektor/CFO | 01.01.2013 |
Financial Executives International of Fort Worth Chapter | Präsident | - |
Ausbildung von Carol Stuckley
Fox School of Business | Graduate Degree |
University of Delaware | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
IPSEN | Health Technology |
PFIZER, INC. | Health Technology |
CENTESSA PHARMACEUTICALS PLC | Health Technology |
TRANSGENE | Health Technology |
Private Unternehmen | 4 |
---|---|
Healthcare Payment Specialists LLC
Healthcare Payment Specialists LLC Miscellaneous Commercial ServicesCommercial Services Healthcare Payment Specialists LLC provides payment and reimbursement solutions. The firm’s solutions include Stingary SAAS, Medicare bad debt, Medicare disproportionate share, Shadow billing compliance, Transfer DRG, Volume decrease adjustment and Complex drug review. It also offers consulting services. The company was founded in 2002 by Peter Jarvis and is headquartered in Fort Worth, TX. | Commercial Services |
Galderma Laboratories LP
Galderma Laboratories LP Pharmaceuticals: MajorHealth Technology Galderma Laboratories LP develops and markets dermatology and prescription products. It also offers treatments for skin conditions such as acne, rosacea, atopic dermatitis, soriasis, melasma and sunspots. Galderma Laboratories was founded in 1961 and is headquartered in Fort Worth, TX. | Health Technology |
Financial Executives International of Fort Worth Chapter | |
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |